Aridis Pharmaceuticals: Reporting Positive Top-Line Results from Phase 2a Study in Cystic Fibrosis
Mar. 29, 2023
Aridis Pharmaceuticals (NASDAQ: ARDS) is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidates for the treatment (AR-301) and prevention (AR-320) of S. aureus bacterial pneumonia showed safety and strong trend toward efficacy in phase 2 clinical trials and are currently in global Phase 3 studies. Phase 3 data of AR-301 is expected in December 2022. The Company is initiated a global Phase 3 registrational trial of AR-320 in 1H22, which is being funded for up to $30 million by the European Commission. It’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. ARDS also has a phase 2 asset for the treatment of cystic fibrosis (AR-501), which is funded by the Cystic Fibrosis Foundation for $7.5 million. Phase 1 study in health adults showed that AR-501 was safe and well tolerated. Phase 2a safety and efficacy data are expected in late 2022. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial with its novel inhalation antibody cocktail technology AR-701 for emerging COVID-19 variants, including the Delta and Omicron variants. The broad COVID variants and pan-coronavirus coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-701 COVID treatment offering. Visit AridisPharmaInfo.com to learn more.
